Estrone C15 derivatives-A new class of 17β-hydroxysteroid dehydrogenase type 1 inhibitors

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 216-224

  Messinger, Josef ^a   Husen, Bettina ^a   Koskimies, Pasi ^b   Hirvelä, Leena ^b   Kallio, Lila ^b   Saarenketo, Pauli ^c   Thole, Hubert ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

^b Hormos Medical Ltd Subsidiary of QuatRx Pharmaceuticals   (Finland)

^c FBD Ltd   (Finland)

Author keywords

17 Hydroxysteroid dehydrogenase; Estrogen; Estrone; Inhibitor

Indexed keywords

ENZYME INHIBITOR; ESTRADIOL; ESTRONE C15 DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; IC 50; MOLECULAR MODEL; PRIORITY JOURNAL;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; ESTRADIOL; ESTRADIOL DEHYDROGENASES; ESTRONE; HUMANS; MODELS, MOLECULAR;

EID: 60249086367     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.10.022     Document Type: Article

References (34)

1. Allan G.M., Bubert C., Vicker N., Smith A., Tutill H.J., Purohit A., Reed M.J., and Potter B.V. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 248 1-2 (2006) 204-207
2. Allan G.M., Lawrence H.R., Cornet J., Bubert C., Fischer D.S., Vicker N., Smith A., Tutill H.J., Purohit A., Day J.M., Mahon M.F., Reed M.J., and Potter B.V. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 49 4 (2006) 1325-1345
3. Bermann H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The Protein Data Bank. Nucleic Acids Res. 28 (2000) 235-242 PDB ID: 17 beta HSD1: 1A27, 1BHS, 1DHT, 1EQU, 1FDS, 1FDS, 1FDT, 1FDU, 1FDV, 1FDW, 1I5R, 1IOL, 1QYV, 1QYW, 1QYX, 3DHE, ER: '1A52', '1ERE', '1ERR', '1G50',' 1GWQ', '1GWR', '1HJ1', '1L2J', '1NDE', '1PCG', '1QKM', '1QKN', '1QKT', '1QKU', '1R5K', '1S9P', '1S9Q', '1SJ0', '1U3Q', '1U3R', '1U3S', '1U9E', '1UOM', '1X76', '1X78', '1X7B', '1X7E', '1X7J', '1X7R', '1XP1', '1XP6', '1XP9', '1XPC', '1XQC', '1YIM', '1YIN', '1YY4', '1YYE', '1ZAF', '2AYR', '3ERD', '3ERT'
4. Bojack G., and Künzer H. An oxy-cope rearrangement approach to C(15) α-alkylated derivatives of estradiol. Tetrahedron Lett. 35 48 (1994) 9025-9026
5. Breton R., Housset D., Mazza C., and Fontecilla-Camps J.C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure 4 8 (1996) 905-915
6. Brozic P., Lanisnik Rizner T., and Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr. Med. Chem. 15 2 (2008) 137-150
7. Burow M.E., Boue S.M., Collins-Burow B.M., Melnik L.I., Duong B.N., Carter-Wientjes C.H., Li S., Wiese T.E., Cleveland T.E., and McLachlan J.A. Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J. Clin. Endocrinol. Metab. 86 4 (2001) 1750-1758
8. Cantrall E.W., Littell R., and Bernstein S. The synthesis of C-15 β-substituted 1,3,5(10)-estratrienes I. J. Org. Chem. 29 (1964) 64
9. Cantrall E.W., Littell R., and Bernstein S. The synthesis of C-15 β-substituted 1,3,5(10)-estratrienes II. J. Org. Chem. 29 (1964) 214
10. Gunnarsson C., Hellqvist E., and Stal O. 17Beta-hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Br. J. Cancer 92 3 (2005) 547-552
11. Gunnarsson C., Jerevall P.L., Hammar K., Olsson B., Nordenskjöld B., Jansson A., and Stål O. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res. Treat. 108 1 (2008) 35-41
12. Hirvelä, L., Johansson, N., Koskimies, P., Pentikäinen, O.T., Nyrönen, T., Salminen, T.A., Johnson, M.S., 2005. Novel compounds and their use in therapy, WO2005032527
13. Husen B., Huhtinen K., Saloniemi T., Messinger J., Thole H.H., and Poutanen M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 147 11 (2006) 5333-5339
14. Husen B., Huhtinen K., Poutanen M., Kangas L., Messinger J., and Thole H. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol. Cell. Endocrinol. 248 1-2 (2006) 109-113
15. Kasai T., Shozu M., Murakami K., Segawa T., Shinohara K., Nomura K., and Inoue M. Increased expression of type I 17beta-hydroxysteroid dehydrogenase enhances in situ production of estradiol in uterine leiomyoma. J. Clin. Endocrinol. Metab. 89 11 (2004) 5661-5668
16. Kirschning A., Harmrolfs K., Mennecke K., Messinger J., Schön U., and Grela K. Homo- and heterogeneous Ru-base metathesis catalysts in cross metathesis of 15.allylestrone-towards 17β-hydroxysteroid dehydrogenase type 1 inhibitors. Tetrahedron Lett. 49 (2008) 3019-3022
17. Lauson H.D., Heller C.G., Golden J.B., and Severinghaus E.L. The immature rat uterus in the assay of estrogenic substances, a comparison of estradiol, estrone and estriol. Endocrinology 24 (1939) 35-44
18. Lehtonen J.V., Still D.J., Rantanen V.V., Ekholm J., Björklund D., Iftikhar Z., Huhtala M., Repo S., Jussila A., Jaakkola J., Pentikäinen O., Nyrönen T., Salminen T., Gyllenberg M., and Johnson M. BODIL: a molecular modeling environment for structure-function analysis and drug design. J. Comput. Aided Mol. Des. 18 6 (2004) 401-419
19. Lu M.L., Huang Y.W., and Lin S.X. Purification, reconstitution, and steady-state kinetics of the trans-membrane 17 beta-hydroxysteroid dehydrogenase 2. J. Biol. Chem. 277 25 (2002) 22123-22130
20. Luu-The V., Zhang Y., Poirier D., and Labrie F. Characteristics of human types 1,2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol. 5 5-6 (1995) 581-587
21. Marrian G.F., and Haslewood G.A.D. The chemistry of estrin. VI. The ring structure of crystalline trihydroxy- and ketohydroxyestrin. J. Soc. Chem. Ind. Trans. 51 (1932) 277
22. Martel C., Rhéaume E., Takahashi M., Trudel C., Couët J., Luu-The V., Simard J., and Labrie F. Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues. J. Steroid Biochem. Mol. Biol. 41 3-8 (1992) 597-603
23. Messinger, J., Thole, H.H., Husen, B., Van Steen, B.J., Schneider, G., Hulshoff, J.B.E., Koskimies, P., Johansson, N., Adamski, J. 2005. Novel 17β-hydroxysteroid dehydrogenase type I inhibitors, WO05047303.
24. Messinger J., Hirvelä L., Husen B., Kangas L., Koskimies P., Pentikäiinen O., Saarenketo P., and Thole H. New inhibitors of 17β-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol. 248 (2006) 192-198
25. Miettinen M.M., Mustonen M.V., Poutanen M.H., Isomaa V.V., and Vihko R.K. Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem. J. 314 (1996) 839-845
26. Pelletier J.D., and Poirier D. Synthesis and evaluation of estradiol derivatives with 16 alpha-(bromoalkylamide), 16 alpha-(bromoalkyl) or 16 alpha-(bromoalkynyl) side chain as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 without estrogenic activity. Bioorg. Med. Chem. 4 10 (1996) 1617-1628
27. Penning T.M. 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocr. Relat. Cancer 3 (1996) 41-56
28. Poirier D., Mérand Y., and Labrie F. Synthesis of 17β-estradiol derivatives with N-butyl,N-methyl alkylamide side chain at position 15. Tetrahedron 47 37 (1991) 7751-7766
29. Poirier D., Mérand Y., Labrie C., and Labrie F. D-ring alkylamine derivatives of estradiol: effect on er-binding affinity and antiestrogenic activity. Bioorg. Med. Chem. Lett. 6 21 (1996) 2537-2542
30. Poirier D. Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 6 (2003) 453-477
31. Sasano H., Frost A.R., Saitoh R., Harada N., Poutanen M., Vihko R., Bulun S.E., Silverberg S.G., and Nagura H. Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J. Clin. Endocrinol. Metab. 81 11 (1996) 4042-4046
32. Smuc T., Pucelj M.R., Sinkovec J., Husen B., Thole H., and Rizner T.L. Expression analysis of the genes involved in estradiol and progesterone action in human ovarian endometriosis. Gynecol. Endocrinol. 23 2 (2007) 105-111
33. Tanenbaum D.M., Wang Y., Williams S.P., and Sigler P.B. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl. Acad. Sci. USA 95 11 (1998) 5998-6003
34. Tsuchiya M., Nakao H., Katoh T., Sasaki H., Hiroshima M., Tanaka T., Matsunaga T., Hanaoka T., Tsugane S., and Ikenoue T. Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19. Hum. Reprod. 20 4 (2005) 974-978